CAS NO: | 101-31-5 |
规格: | ≥98% |
包装 | 价格(元) |
250mg | 电议 |
500mg | 电议 |
1g | 电议 |
2g | 电议 |
5g | 电议 |
10g | 电议 |
Molecular Weight (MW) | 289.37 |
---|---|
Formula | C17H23NO3 |
CAS No. | 101-31-5 |
Storage | -20℃ for 3 years in powder form |
-80℃ for 2 years in solvent | |
Solubility (In vitro) | DMSO: 58 mg/mL (200.4 mM) |
Water: <1 mg/mL | |
Ethanol: 58 mg/mL (200.4 mM) | |
Solubility (In vivo) | 30% Propylene glycol, 5% Tween 80, 65% D5W: 5 mg/mL |
Synonyms | Daturine |
In Vitro | In vitro activity: -hyoscyamine increases the turnover number of GTPase activity from 0.19 min-1 to 2.11 min-1 in the steady-state kinetic measurements. R-(+)-hyoscyamine results in displacement of [3H]NMS binding to the muscarinic acetylcholine receptor subtypes (m1-m5) with pKi value of 8.67, 8.51, 7.46, 8.56 and 8.53, respectively. Hyoscyamine prevents the agonist-induced stimulation of cAMP production with EC50 of 7.8 nM in CHO cells. S-(-)-hyoscyamine enhances the forskolin-stimulated synthesis of cyclic AMP in rat cardiac (both atrial and ventricular) membranes by up to 24%. |
---|---|
In Vivo | L-hyoscyamine (20 mg/kg) prolongs migrating myoelectric complex (MMC) cycle length from 17.6 min to 29.0 min in conscious rats. |
Animal model | Rat |
Formulation & Dosage | Dissolved in saline; 20 mg/kg; i.v. injection |
References | Biochemistry. 1987 Dec 15;26(25):8175-82; Eur J Pharmacol. 2003 Apr 25;467(1-3):211-8. |